Affiliation:
1. Swiss Tropical and Public Health Institute, Allschwil, Switzerland
2. University of Basel, Basel, Switzerland
Abstract
ABSTRACT
Neglected tropical diseases caused by trypanosomatid parasites have devastating health and economic consequences, especially in tropical areas. New drugs or new combination therapies to fight these parasites are urgently needed. Venturicidin A, a macrolide extracted from
Streptomyces
, inhibits the ATP synthase complex of fungi and bacteria. However, its effect on trypanosomatids is not fully understood. In this study, we tested venturicidin A on a panel of trypanosomatid parasites using Alamar Blue assays and found it to be highly active against
Trypanosoma brucei
and
Leishmania donovani
, but much less so against
Trypanosoma evansi
. Using fluorescence microscopy, we observed a rapid loss of the mitochondrial membrane potential in
T. brucei
bloodstream forms upon venturicidin A treatment. Additionally, we report the loss of mitochondrial DNA in approximately 40%–50% of the treated parasites. We conclude that venturicidin A targets the ATP synthase of
T. brucei
, and we suggest that this macrolide could be a candidate for anti-trypanosomatid drug repurposing, drug combinations, or medicinal chemistry programs.
Funder
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Publisher
American Society for Microbiology